Please ensure Javascript is enabled for purposes of website accessibility

GenVec’s loss increases in 4th quarter

GenVec Inc., of Gaithersburg, a biopharmaceutical company developing novel gene-based drugs and vaccines, reported a fourth-quarter net loss totaling $3.2 million, or 26 percent more than the net loss of $2.5 million it reported in the 2011 quarter.

On a per-share basis, the loss was 24 cents in the 2012 quarter versus 19 cents per share for the same period in 2011.

Revenue totaled $1.5 million in the 2012 fourth quarter versus $3.4 million in the prior-year period.

A single analyst polled by Thomson Reuters had forecast a net loss of 27 cents per share on revenue of $3.7 million.